检索结果-南通市图书馆

World Journal of Diabetes 2022年第12期13卷 1096-1105页

作者： Maja Cigrovski Berkovic Ines Bilic-Curcic Anna Mrzljak silvija canecki varzic Vjekoslav Cigrovski Department of Endocrinology Diabetes and Clinical PharmacologyClinical Hospital DubravaZagreb 10000Croatia Faculty of Kinesiology University of ZagrebZagreb 10000Croatia Faculty of Medicine University of Osijek Osijek 31000Croatia Department of Endocrinology and Diabetes Clinical Hospital Centre OsijekOsijek 31000Croatia Department of Gastroenterology and Hepatology University Hospital Center ZagrebZagreb 10000Croatia School of Medicine University of ZagrebZagreb 10000Croatia

Bariatric surgery offers the best health results in overweight and obese patients but is not a risk and/or complication-free *** cases with additional hyperglycemia,the burden of surgery can be even higher and alter both shortterm and long-term *** bariatric surgery offers glycemic improvements and in the case of early onset diabetes disease remission,weight loss results are lower than for obese patients without *** multimodal programs,usually including interventions related to patients’performance,nutritional and psychological status as well as currently available pharmacotherapy before the surgery itself might considerably improve the immediate and late postoperative ***,there are still no clear guidelines addressing the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery and therefore no unique protocols to improve patients’*** this minireview,we summarize the current knowledge on prehabilitation before bariatric surgery procedures in patients with obesity and dysglycemia.

关键词： Bariatric surgery Obesity Dysgylcemia Diabetes outcome Prehabilitation

Effect of COVID-19 on management of type 1 diabetes:Pushing the boundaries of telemedical healthcare

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2021年第6期12卷 780-785页

作者： Ines Bilic Curcic Maja Cigrovski Berkovic Tomislav Kizivat silvija canecki varzic Robert Smolic Martina Smolic Department of Endocrinology University Hospital OsijekOsijek 31000Croatia Department of Pharmacology Faculty of Medicine OsijekOsijek 31000Croatia Department of Endocrinology DiabetesMetabolism and Clinical PharmacologyUniversity Hospital DubravaZagreb 10000Croatia Department of Kinesiological Anthropology and Methodology Faculty of KinesiologyUniversity of ZagrebZagreb 10000Croatia Clinical Institute of Nuclear Medicine and Radiation Protection University Hospital OsijekOsijek 31000Croatia Department of Nuclear Medicine and Oncology Faculty of Medicine OsijekOsijek 31000Croatia Department of Internal Medicine Family Medicineand HistoryFaculty of Medicine OsijekOsijek 31000Croatia Department of Pathophysiology Faculty of Medicine OsijekOsijek 31000Croatia Department of Pathophysiology Physiology and ImmunologyFaculty of Dental Medicine and HealthOsijek 31000Croatia Department of Pharmacology and Biochemistry Faculty of Dental Medicine and HealthOsijek 31000Croatia

The new coronavirus disease 2019(COVID-19)pandemic posed a great burden on health care systems worldwide and is an enormous and real obstacle in providing needed health care to patients with chronic diseases such as *** to COVID-19,there have been great advances in technology used for management of type 1 diabetes,primarily insulin pumps,sensors,integrated and closed loop systems,ambulatory glucose profile software,and smart phone apps providing necessary essentials for telemedicine implementation right at the beginning of the COVID-19 *** results of these remote interventions are reassuring in terms of glycemic management and hemoglobin A1c ***,data on long-term outcomes and cost reductions are missing as well as proper technical infrastructure and government health policy support.

关键词： Diabetes management Telemedicine COVID-19 Diabetes type 1

Obesity Paradox in Chronic Liver Diseases:Product of Bias or a Real Thing?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2019年第3期7卷 275-279页

作者： Ines Bilic Curcic Maja Cigrovski Berkovic Lucija Kuna Hrvoje Roguljic Robert Smolic silvija canecki varzic Lucija Virovic Jukic Martina Smolic Department of Pharmacology Faculty of MedicineJ.J.Strossmayer University of OsijekOsijekCroatia Department of Diabetes Endocrinology and Metabolism DisordersOsijek University Hospital CentreFaculty of MedicineJosip Juraj Strossmayer University of OsijekOsijekCroatia Department for Endocrinology Diabetes and Metabolism University Hospital Center"Sestre Milosrdnice"ZagrebCroatia Department of Pharmacology and Biochemistry Faculty of Dental Medicine and HealthJ.J.Strossmayer University of OsijekOsijekCroatia Department for Cardiovascular Disease Osijek University HospitalOsijekCroatia Department of Gastroenterology and Hepatology Osijek University Hospital CentreFaculty of MedicineJosip Juraj Strossmayer University of OsijekOsijekCroatia Department of Pathophysiology Faculty of MedicineJosip Juraj Strossmayer University of OsijekOsijekCroatia Department of Internal Medicine Faculty of MedicineJosip Juraj Strossmayer University of OsijekOsijekCroatia Department of Gastroenterology and Hepatology Sisters of Mercy University HospitalUniversity of Zagreb School of MedicineZagrebCroatia Department of Pharmacology J.J.Stross-mayer University of Osijek Faculty of Medicine OsijekJ.Huttlera 4Osijek 31000Croatia

In recent years,evidence supporting the theory of obesity paradox has increased,showing that obese/overweight people with prevalent chronic diseases experience lower mortality compared with patients of normal *** far,evidence is most comprehensive in cardiovascular and chronic renal diseases;however,published studies are prone to many biases,enabling us to reach a definite *** data in chronic liver disease is scarce and *** is traditionally associated with nonalcoholic fatty liver disease and steatosis in viral hepatitis and as such one would not expect the obesity paradox to be a real possibility in liver ***,there seem to be new data indicating the opposite-the obesity paradox exists in severe and end-stage liver cirrhosis,which could be attributed to a better lean mass in patients with higher body mass index,meaning that sarcopenia,as one of the most important prognostic factors of survival,is less likely to be ***,the problem of various methodological problems addressing the association between body weight and mortality,which is present both in liver disease and other chronic diseases,are preventing us from attaining an unanimous ***,we should be aware that the obesity paradox might be true,especially in severe and end-stage *** suggests focusing our efforts toward preserving or building up fat-free mass and decreasing infiammatory activity responsible for catabolism and sarcopenia,and implying that the underlaying cause should be treated.

关键词： Obesity paradox Chronic liver disease NAFLD NASH Cirrhosis

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2020年第11期11卷 540-552页

作者： Maja Cigrovski Berkovic Ines Bilic-Curcic Tomislav Bozek Davorka Herman Mahecic Sanja KlobucarMajanovic silvija canecki-varzic Jelena Andric Srecko Marusic Anna Mrzljak Faculty of Medicine J.J.Strossmayer University OsijekOsijek 31000Croatia Department for Endocrinology Diabetes and Clinical PharmacologyClinical Hospital DubravaZagreb 10000Croatia Department of Kinesiological Anthropology and Methodology Faculty of KinesiologyUniversity of ZagrebZagreb 10000Croatia Department of Endocrinology and Metabolism Disorders Clinical Hospital CenterOsijek 31000Croatia University Clinic for Diabetes“Vuk Vrhovac” Merkur University HospitalZagreb 10000Croatia School of Medicine University of ZagrebZagreb 10000Croatia Department for Endocrinology Diabetes and MetabolismUniversity Hospital Centre“Sestre milosrdnice”Zagreb 10000Croatia Department for Endocrinology Diabetes and MetabolismUniversity Hospital Centre RijekaSchool of MedicineUniversity of Rijeka51000 RijekaCroatia Department of Medicine Merkur University HospitalSchool of MedicineUniversity of ZagrebZagreb 10000Croatia

BACKGROUND The sodium/glucose cotransporter-2 inhibitors(SGLT-2i)and glucagon-like-1 receptor agonists(GLP-1RA)are antidiabetic agents effective both in hemoglobin A1c(HbA1c)reduction(with a low risk of hypoglycemia)and cardiovascular event *** patients with type 2 diabetes,the add-on value of combination therapy of GLP-1RA and an SGLT-2i seems *** To investigate whether the efficacy of GLP-1RA and SGLT-2i combination observed in randomized controlled trials translates into therapeutic benefits in the Croatian population during routine clinical practice and *** We included 200 type 2 diabetes patients with poor glycemic control and analyzed the effects of treatment intensification with(1)GLP-1RA on top of SGLT-2i,(2)SGLT-2i on top of GLP-1RA compared to(3)simultaneous addition of both *** primary study endpoint was the proportion of participants with HbA1c<7.0%and/or 5%bodyweight *** outcomes included changes in fasting plasma glucose(FPG),prandial plasma glucose,lowdensity lipoprotein cholesterol,estimated glomerular filtration rate(eGFR),and cardiovascular(CV)incidents assessment over a follow-up period of 12 *** The majority of patients were over 65-years-old,had diabetes duration for more than 10 *** initial body mass index was 39.41±5.49 kg/m2 and HbA1c 8.32±1.26%.Around half of the patients in all three groups achieved target HbA1c below 7%.A more pronounced decrease in the HbA1c seen with simultaneous SGLT-2i and GLP-1RA therapy was a result of higher baseline HbA1c and not the effect of initiating combination *** number of patients achieving FPG below 7.0 mmol/L was significantly higher in the SGLT-2i group(P=0.021),and 5%weight loss was dominantly achieved in the simultaneous therapy group(P=0.044).A composite outcome(reduction of HbA1c below 7%(53 mmol/mol)with 5%weight loss)was achieved in 32.3%of total patients included in the *** 18.2%of patients attained composite outc

关键词： Sodium/glucose cotransporter-2 inhibitors Glucagon-like-1 receptor agonists Type 2 diabetes mellitus Body weight Glycemic control Cardiovascular complications